These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 20945948)

  • 1. Telaprevir.
    Drugs R D; 2010; 10(3):179-202. PubMed ID: 20945948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Boceprevir.
    Drugs R D; 2010; 10(3):203-10. PubMed ID: 20945949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adding telaprevir improves cure rate in patient with HCV infection.
    AIDS Patient Care STDS; 2010 Dec; 24(12):807. PubMed ID: 21188771
    [No Abstract]   [Full Text] [Related]  

  • 4. Telaprevir for chronic hepatitis C virus infection.
    Jesudian AB; Jacobson IM
    Clin Liver Dis; 2013 Feb; 17(1):47-62. PubMed ID: 23177282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telaprevir: a review of its use in the management of genotype 1 chronic hepatitis C.
    Perry CM
    Drugs; 2012 Mar; 72(5):619-41. PubMed ID: 22439668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview of the PROVE studies evaluating the use of telaprevir in chronic hepatitis C genotype 1 patients.
    Burney T; Dusheiko G
    Expert Rev Anti Infect Ther; 2011 Feb; 9(2):151-60. PubMed ID: 21143041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and safety of telaprevir-based regimens for treating chronic hepatitis C virus genotype 1 infection: a meta-analysis of randomized trials.
    Yang D; Liang HJ; Li D; Wei X; Ma L; Jia Z
    Intern Med; 2013; 52(6):653-60. PubMed ID: 23503406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telaprevir for the treatment of chronic hepatitis C infection.
    Muir AJ
    Expert Rev Anti Infect Ther; 2011 Dec; 9(12):1105-14. PubMed ID: 22114960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SILEN-C3, a phase 2 randomized trial with faldaprevir plus pegylated interferon α-2a and ribavirin in treatment-naive hepatitis C virus genotype 1-infected patients.
    Dieterich D; Asselah T; Guyader D; Berg T; Schuchmann M; Mauss S; Ratziu V; Ferenci P; Larrey D; Maieron A; Stern JO; Ozan M; Datsenko Y; Böcher WO; Steinmann G
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3429-36. PubMed ID: 24709256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease.
    Lin C; Kwong AD; Perni RB
    Infect Disord Drug Targets; 2006 Mar; 6(1):3-16. PubMed ID: 16787300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.
    Jacobson IM; Dore GJ; Foster GR; Fried MW; Radu M; Rafalsky VV; Moroz L; Craxi A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Scott J; Sinha R; Beumont-Mauviel M
    Lancet; 2014 Aug; 384(9941):403-13. PubMed ID: 24907225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal treatment with telaprevir for chronic HCV infection.
    Jesudian AB; Jacobson IM
    Liver Int; 2013 Feb; 33 Suppl 1():3-13. PubMed ID: 23286840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telaprevir for previously untreated chronic hepatitis C virus infection.
    Jacobson IM; McHutchison JG; Dusheiko G; Di Bisceglie AM; Reddy KR; Bzowej NH; Marcellin P; Muir AJ; Ferenci P; Flisiak R; George J; Rizzetto M; Shouval D; Sola R; Terg RA; Yoshida EM; Adda N; Bengtsson L; Sankoh AJ; Kieffer TL; George S; Kauffman RS; Zeuzem S;
    N Engl J Med; 2011 Jun; 364(25):2405-16. PubMed ID: 21696307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple therapy with first generation HCV protease inhibitors: lead-in or no lead-in phase?
    Pascale A; Serfaty L
    J Hepatol; 2013 Feb; 58(2):391-4. PubMed ID: 23063419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Telaprevir user's guide.
    Liapakis AM; Jacobson I
    Liver Int; 2012 Feb; 32 Suppl 1():17-25. PubMed ID: 22212567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telaprevir (Incivek) and boceprevir (Victrelis) for chronic hepatitis C.
    Med Lett Drugs Ther; 2011 Jul; 53(1369):57-9. PubMed ID: 21778964
    [No Abstract]   [Full Text] [Related]  

  • 17. Telaprevir: looking for a sustained virologic response in hepatitis C virus infection.
    Nehra V; Rizza SA; Talwani R; Temesgen Z
    Drugs Today (Barc); 2011 Nov; 47(11):829-37. PubMed ID: 22146226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telaprevir activity in treatment-naive patients infected hepatitis C virus genotype 4: a randomized trial.
    Benhamou Y; Moussalli J; Ratziu V; Lebray P; De Backer K; De Meyer S; Ghys A; Luo D; Picchio GR; Beumont M
    J Infect Dis; 2013 Sep; 208(6):1000-7. PubMed ID: 23801602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telaprevir for retreatment of HCV infection.
    Zeuzem S; Andreone P; Pol S; Lawitz E; Diago M; Roberts S; Focaccia R; Younossi Z; Foster GR; Horban A; Ferenci P; Nevens F; Müllhaupt B; Pockros P; Terg R; Shouval D; van Hoek B; Weiland O; Van Heeswijk R; De Meyer S; Luo D; Boogaerts G; Polo R; Picchio G; Beumont M;
    N Engl J Med; 2011 Jun; 364(25):2417-28. PubMed ID: 21696308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus.
    Barritt AS; Fried MW
    Gastroenterology; 2012 May; 142(6):1314-1323.e1. PubMed ID: 22537438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.